linsitinib

{{Chembox

| ImageFile = Linsitinib.svg

| ImageSize = 180px

| PIN = (1s,3s)-3-[8-Amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutan-1-ol

| OtherNames = OSI-906

|Section1={{Chembox Identifiers

| CASNo = 867160-71-2

| CASNo_Ref = {{cascite|correct|}}

| DrugBank = DB06075

| PubChem = 11640390

| ChEMBL = 1091644

| ChemSpiderID = 21391708

| KEGG = D09925

| UNII = 15A52GPT8T

| ChEBI = 91402

| SMILES = C[C@]1(C[C@@H](C1)C2=NC(=C3N2C=CN=C3N)C4=CC5=C(C=CC(=N5)C6=CC=CC=C6)C=C4)O

| InChI = 1/C26H23N5O/c1-26(32)14-19(15-26)25-30-22(23-24(27)28-11-12-31(23)25)18-8-7-17-9-10-20(29-21(17)13-18)16-5-3-2-4-6-16/h2-13,19,32H,14-15H2,1H3,(H2,27,28)/t19-,26+

| InChIKey = PKCDDUHJAFVJJB-VLZXCDOPBI

| StdInChI = 1S/C26H23N5O/c1-26(32)14-19(15-26)25-30-22(23-24(27)28-11-12-31(23)25)18-8-7-17-9-10-20(29-21(17)13-18)16-5-3-2-4-6-16/h2-13,19,32H,14-15H2,1H3,(H2,27,28)

| StdInChIKey = PKCDDUHJAFVJJB-UHFFFAOYSA-N

}}

|Section2={{Chembox Properties

| C=26 | H=23 | N=5 | O=1

| Appearance =

| Density =

| MeltingPt =

| BoilingPt =

| Solubility =

}}

|Section3={{Chembox Hazards

| MainHazards =

| FlashPt =

| AutoignitionPt =

}}

}}

Linsitinib is an experimental drug candidate for the treatment of various types of cancer. It is an inhibitor of the insulin receptor and of the insulin-like growth factor 1 receptor (IGF-1R).{{cite journal |last1=Mulvihill |first1=Mark J |last2=Cooke |first2=Andrew |last3=Rosenfeld-Franklin |first3=Maryland |last4=Buck |first4=Elizabeth |last5=Foreman |first5=Ken |last6=Landfair |first6=Darla |last7=O’Connor |first7=Matthew |last8=Pirritt |first8=Caroline |last9=Sun |first9=Yingchaun |last10=Yao |first10=Yan |last11=Arnold |first11=Lee D |last12=Gibson |first12=Neil W |last13=Ji |first13=Qun-Sheng |title=Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor |journal=Future Medicinal Chemistry |date=September 2009 |volume=1 |issue=6 |pages=1153–1171 |doi=10.4155/fmc.09.89 |pmid=21425998 }} This prevents tumor cell proliferation and induces tumor cell apoptosis.{{cite web | url = http://www.cancer.gov/drugdictionary?cdrid=566191 | title = Linsitinib | work = NCI Drug Dictionary | publisher = National Cancer Institute | access-date = October 16, 2012}}

Linsitinib was granted orphan drug designation for adrenocortical carcinoma in March 2012.{{cite web|url=http://adisinsight.springer.com/drugs/800026466|title=Linsitinib - AdisInsight|website=adisinsight.springer.com}}

Phase II clinical trials were initiated for multiple myeloma, ovarian cancer, hepatocellular carcinoma, and NSCLC, but subsatisfactory results caused research for these indications to be discontinued. A phase III clinical trial found that linsitinib did not increase survival in patients with adrenocortical carcinoma.{{cite journal |last1=Fassnacht |first1=Martin |last2=Berruti |first2=Alfredo |last3=Baudin |first3=Eric |last4=Demeure |first4=Michael J |last5=Gilbert |first5=Jill |last6=Haak |first6=Harm |last7=Kroiss |first7=Matthias |last8=Quinn |first8=David I |last9=Hesseltine |first9=Elizabeth |last10=Ronchi |first10=Cristina L |last11=Terzolo |first11=Massimo |author12=Toni Choueiri|last13=Poondru |first13=Srinivasu |last14=Fleege |first14=Tanya |last15=Rorig |first15=Ramona |last16=Chen |first16=Jihong |last17=Stephens |first17=Andrew W |last18=Worden |first18=Francis |last19=Hammer |first19=Gary D |title=Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study |journal=The Lancet Oncology |date=April 2015 |volume=16 |issue=4 |pages=426–435 |doi=10.1016/S1470-2045(15)70081-1 |pmid=25795408 |hdl=2318/1534804 |hdl-access=free }} As of 2017, no clinical trials were in progress.